Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

Table 5

Main parameters used in the base case scenario.

Age (years)—mean	34.7
Gender (% female)	93.9%
Length of disease (years)—mean	6.6
Age at the moment of the diagnosis (years)—mean	28.1
% Afro-Caribbean	7.3%
SLICC (Systemic Lupus International Collaborating Clinics Damage—mean Index)	0.61
SLEDAI—mean	10.9
Daily steroid dose (mg/day)—mean	11.6

The characteristics are determined by pooling the patient-level data from BLISS-52 and BLISS-76 for placebo and belimumab 10 mg/kg.